JP Patent

JP7179035B2 — 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン

Assigned to ハー・ルンドベック・アクチエゼルスカベット · Expires 2022-11-28 · 3y expired

What this patent protects

Patent listed against vortioxetine-hydrobromide.

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: JP7179035B2
Jurisdiction: JP
Classification: —
Expires: 2022-11-28
Drug substance claim: No
Drug product claim: No
Assignee: ハー・ルンドベック・アクチエゼルスカベット
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.